Common genetic variability in ESR1 and EGF in relation to endometrial cancer risk and survival

British Journal of Cancer

Volumn 100, Issue 8, 2009, Pages 1358-1364

  Einarsdottir K ^a   Darabi, H ^b   Czene, K ^b   Li, Y ^c   Low, Y L ^d   Li, Y Q ^c   Bonnard, C ^c   Wedren S ^b   Liu, E T ^c   Hall, P ^b   Liu, J ^c   Humphreys, K ^b  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b KAROLINSKA INSTITUTE   (Sweden)

^c GENOME INSTITUTE OF SINGAPORE   (Singapore)

^d AGENCY FOR SCIENCE   (Singapore)

Author keywords

EGF; Endometrial cancer; ESR1; Polymorphism; Survival

Indexed keywords

EPIDERMAL GROWTH FACTOR;

ADULT; AGED; ARTICLE; CANCER RISK; CANCER SURVIVAL; CONTROLLED STUDY; DYING; EGF GENE; ENDOMETRIUM CANCER; ESR1 GENE; FEMALE; GENE; GENE LINKAGE DISEQUILIBRIUM; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; HUMAN TISSUE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MYOMETRIUM; POPULATION; POPULATION DYNAMICS; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; SINGLE NUCLEOTIDE POLYMORPHISM; SWEDEN;

AGED; CASE-CONTROL STUDIES; ENDOMETRIAL NEOPLASMS; EPIDERMAL GROWTH FACTOR; ESTROGEN RECEPTOR ALPHA; FEMALE; GENETIC VARIATION; GENOTYPE; HUMANS; MIDDLE AGED; NEOPLASM INVASIVENESS; POLYMORPHISM, SINGLE NUCLEOTIDE; REGISTRIES; RISK FACTORS; SURVIVAL ANALYSIS; SWEDEN;

EID: 64949137020     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6604984     Document Type: Article

References (34)

1. Clayton D, Chapman J, Cooper J (2004) Use of unphased multilocus genotype data in indirect association studies. Genet Epidemiol 27: 415-428
2. Costa BM, Ferreira P, Costa S, Canedo P, Oliveira P, Silva A, Pardal F, Suriano G, Machado JC, Lopes JM, Reis RM (2007) Association between functional EGF+61 polymorphism and glioma risk. Clin Cancer Res 13: 2621-2626
3. Curtis SW, Washburn T, Sewall C, Di Augustine R, Lindzey J, Couse JF, Korach KS (1996) Physiological coupling of growth factor and steroid receptor signaling pathways: estrogen receptor knockout mice lack estrogen-like response to epidermal growth factor. Proc Natl Acad Sci USA 93: 12626-12630
4. Dickson RB, Lippman ME (1998) Growth regulation of normal and malignant breast epithelium. In The Breast: Comprehensive Management of Benign and Malignant Diseases, Bland KI, Copeland EM (eds), pp 518-536. Saunders: Philadelphia
5. Einarsdóttir K, Darabi H, Li Y, Low YL, Li YQ, Bonnard C, Sjölander A, Czene K, Wedrén S, Liu ET, Hall P, Humphreys K, Liu J (2008) ESR1 and EGF genetic variation in relation to breast cancer risk and survival. Breast Cancer Res 10: R15
6. Einarsdottir K, Humphreys K, Bonnard C, Li Y, Li Y, Chia KS, Liu ET, Hall P, Liu J, Wedren S (2007) Effect of ATM, CHEK2 and ERBB2 TAGSNPs and haplotypes on endometrial cancer risk. Hum Mol Genet 16: 154-164
7. Gabriel SB, Schaffner SF, Nguyen H, Moore JM, Roy J, Blumenstiel B, Higgins J, DeFelice M, Lochner A, Faggart M, Liu-Cordero SN, Rotimi C, Adeyemo A, Cooper R, Ward R, Lander ES, Daly MJ, Altshuler D (2002) The structure of haplotype blocks in the human genome. Science 296: 2225-2229
8. Hamai Y, Matsumura S, Matsusaki K, Kitadai Y, Yoshida K, Yamaguchi Y, Imai K, Nakachi K, Toge T, Yasui W (2005) A single nucleotide polymorphism in the 5' untranslated region of the EGF gene is associated with occurrence and malignant progression of gastric cancer. Pathobiology 72: 133-138
9. Hernan MA, Hernandez-Diaz S, Werler MM, Mitchell AA (2002) Causal knowledge as a prerequisite for confounding evaluation: an application to birth defects epidemiology. Am J Epidemiol 155: 176-184
10. Herrington DM, Howard TD, Brosnihan KB, McDonnell DP, Li X, Hawkins GA, Reboussin DM, Xu J, Zheng SL, Meyers DA, Bleecker ER (2002) Common estrogen receptor polymorphism augments effects of hormone replacement therapy on E-selectin but not C-reactive protein. Circulation 105: 1879-1882
11. Ignar-Trowbridge DM, Nelson KG, Bidwell MC, Curtis SW, Washburn TF, McLachlan JA, Korach KS (1992) Coupling of dual signaling pathways: epidermal growth factor action involves the estrogen receptor. Proc Natl Acad Sci USA 89: 4658-4662
12. Iles MM (2006) Obtaining unbiased estimates of tagging SNP performance. Ann Hum Genet 70: 254-261
13. Isola J, De Vries S, Chu L, Ghazvini S, Waldman F (1994) Analysis of changes in DNA sequence copy number by comparative genomic hybridization in archival paraffin-embedded tumor samples. Am J Pathol 145: 1301-1308
14. Iwamoto I, Fujino T, Douchi T, Nagata Y (2003) Association of estrogen receptor alpha and beta3-adrenergic receptor polymorphisms with endometrial cancer. Obstet Gynecol 102: 506-511
15. Jain M, Kumar S, Upadhyay R, Lal P, Tiwari A, Ghoshal UC, Mittal B (2007) Influence of apoptosis (BCL2, FAS), cell cycle (CCND1) and growth factor (EGF, EGFR) genetic polymorphisms on survival outcome: an exploratory study in squamous cell esophageal cancer. Cancer Biol Ther 6: 1553-1558
16. Jin G, Miao R, Deng Y, Hu Z, Zhou Y, Tan Y, Wang J, Hua Z, Ding W, Wang L, Chen W, Shen J, Wang X, Xu Y, Shen H (2007) Variant genotypes and haplotypes of the epidermal growth factor gene promoter are associated with a decreased risk of gastric cancer in a high-risk Chinese population. Cancer Sci 98: 864-868
17. Marquez DC, Lee J, Lin T, Pietras RJ (2001) Epidermal growth factor receptor and tyrosine phosphorylation of estrogen receptor. Endocrine 16: 73-81
18. Matsuzaki S, Fukaya T, Suzuki T, Murakami T, Sasano H, Yajima A (1999) Oestrogen receptor alpha and beta mRNA expression in human endometrium throughout the menstrual cycle. Mol Hum Reprod 5:559-564
19. Nelson KG, Takahashi T, Bossert NL, Walmer DK, McLachlan JA (1991) Epidermal growth factor replaces estrogen in the stimulation of female genital-tract growth and differentiation. Proc Natl Acad Sci USA 88: 21-25
20. Nystrom L, Larsson LG, Rutqvist LE, Lindgren A, Lindqvist M, Ryden S, Andersson I, Bjurstam N, Fagerberg G, Frisell J (1995) Determination of cause of death among breast cancer cases in the Swedish randomized mammography screening trials. A comparison between official statistics and validation by an endpoint committee. Acta Oncol 34: 145-152
21. Okamoto I, Roka F, Krogler J, Endler G, Kaufmann S, Tockner S, Marsik C, Jilma B, Mannhalter C, Wagner O, Pehamberger H (2006) The EGF A61G polymorphism is associated with disease-free period and survival in malignant melanoma. J Invest Dermatol 126: 2242-2246
22. Persson I (2000) Estrogens in the causation of breast, endometrial and ovarian cancers - evidence and hypotheses from epidemiological findings. J Steroid Biochem Mol Biol 74: 357-364
23. Qin ZS, Niu T, Liu JS (2002) Partition-ligation-expectation-maximization algorithm for haplotype inference with single-nucleotide polymorphisms. Am J Hum Genet 71: 1242-1247
24. Sasaki M, Tanaka Y, Kaneuchi M, Sakuragi N, Dahiya R (2002) Polymorphisms of estrogen receptor alpha gene in endometrial cancer. Biochem Biophys Res Commun 297: 558-564
25. Shahbazi M, Pravica V, Nasreen N, Fakhoury H, Fryer AA, Strange RC, Hutchinson PE, Osborne JE, Lear JT, Smith AG, Hutchinson IV (2002) Association between functional polymorphism in EGF gene and malignant melanoma. Lancet 359: 397-401
26. Statistics Sweden (2004) Immigration and Emigration in the Postwar Period. Statistiska Centralbyrån (SCB): Stockholm, Sweden
27. Stram DO, Haiman CA, Hirschhorn JN, Altshuler D, Kolonel LN, Henderson BE, Pike MC (2003) Choosing haplotype-tagging SNPS based on unphased genotype data using a preliminary sample of unrelated subjects with an example from the Multiethnic Cohort Study. Hum Hered 55: 27-36
28. Tanabe KK, Lemoine A, Finkelstein DM, Kawasaki H, Fujii T, Chung RT, Lauwers GY, Kulu Y, Muzikansky A, Kuruppu D, Lanuti M, Goodwin JM, Azoulay D, Fuchs BC (2008) Epidermal growth factor gene functional polymorphism and the risk of hepatocellular carcinoma in patients with cirrhosis. JAMA 299: 53-60
29. Team RDC (2005) R: A language and environment for statistical computing. R Foundation for Statistical Computing: Vienna, Austria
30. The Swedish National Board of Health and Welfare (2006) Cancer Incidence in Sweden 2004. Centre for Epidemiology, Socialstyrelsen: Stockholm, Sweden
31. Vauleon E, Auger N, Benouaich-Amiel A, Laigle-Donadey F, Kaloshi G, Lejeune J, Delattre JY, Thillet J, Sanson M (2007) The 61 A/G EGF polymorphism is functional but is neither a prognostic marker nor a risk factor for glioblastoma. Cancer Genet Cytogenet 172: 33-37
32. Weale ME, Depondt C, Macdonald SJ, Smith A, Lai PS, Shorvon SD, Wood NW, Goldstein DB (2003) Selection and evaluation of tagging SNPs in the neuronal-sodium-channel gene SCN1A: implications for linkage-disequilibrium gene mapping. Am J Hum Genet 73: 551-565
33. Wedrén S, Lovmar L, Humphreys K, Magnusson C, Melhus H, Syvanen A-C, Kindmark A, Landegren U, Lagerstrom Fermer M, Stiger F, Persson I, Baron J, Weiderpass E (2008) Estrogen receptor alpha gene polymorphism and endometrial cancer risk - a case-control study. BMC Cancer 8: 322
34. Weiderpass E, Persson I, Melhus H, Wedren S, Kindmark A, Baron JA (2000) Estrogen receptor alpha gene polymorphisms and endometrial cancer risk. Carcinogenesis 21: 623-627